Albert Heidi
Research Subjects
Research Interests
Albert Heidi has a total of 11 co-authors. Here are the top co-authors by number of shared publications:
R J Mole
2 shared publicationsT Seaman
2 shared publicationsA Jordaan
1 shared publicationA P Trollip
1 shared publicationA Trollip
1 shared publicationC Abrahams
1 shared publication
Latest Publications
- 1 September 2007
- Vol. 97 (9) , 858-63
Evaluation of a rapid screening test for rifampicin resistance in re-treatment tuberculosis patients in the Eastern Cape.
Patients with multidrug-resistant (MDR) tuberculosis (TB) are at high risk of treatment failure. It is anticipated that early identification of MDR-TB and appropriate treatment will improve patient outcome and disease control. We evaluated the rapid detection of rifampicin resistance in previously treated TB patients, directly from acidfast bacilli (AFB)-positive sputum using a phage-based test, FASTPlaque-Response (Biotec Laboratories Ltd, Ipswich, UK). The ability of rifampicin resistance to predict MDR-TB was also determined. A prospective study was done comparing performance of the rapid phage test with conventional culture and drug susceptibility testing (DST) in AFB-positive TB patients. Five primary health clinics and one TB referral centre in the Port Elizabeth Metropolitan area, Eastern Cape. Sensitivity, specificity and overall accuracy of the phage test were determined compared with gold standard culture and DST. Discrepant results were resolved by molecular detection of mutations conferring rifampicin resistance. The proportion of rifampicin-resistant strains that were MDR was also determined. Previously treated patients were at a high risk of MDRTB (35.7%). Sensitivity, specificity and overall accuracy of FASTPlaque-Response for rifampicin resistance determination were 95.4% (95% confidence interval (CI): 91.0 - 99.8%), 97.2% (95% CI: 94.5 - 99.9%) and 96.5% (95% CI: 94.1 - 98.9%) respectively compared with conventional DST (unresolved), calculated for specimens that had both FASTPlaque-Response and conventional DST results available. FASTPlaque-Response results were available in 2 days instead of 28 - 85 days with conventional DST. However, only 70.6% of FASTPlaque-Response results were interpretable compared with 86.3% of conventional DST results. The majority (95.5%) of rifampicinresistant strains were MDR-TB. Rapid detection of rifampicin resistance using FASTPlaque-Response could contribute to improved management of patients at risk of MDR-TB, such as previously treated patients. However, improvement in control of specimen-related contamination is needed to ensure that a higher proportion of FASTPlaque-Response results are interpretable. Where indicated, early modification of therapy could improve patient prognosis and reduce disease transmission.
- 1 September 2007
- Vol. 97 (9) , 858-63
Evaluation of a rapid screening test for rifampicin resistance in re-treatment tuberculosis patients in the Eastern Cape.
Patients with multidrug-resistant (MDR) tuberculosis (TB) are at high risk of treatment failure. It is anticipated that early identification of MDR-TB and appropriate treatment will improve patient outcome and disease control. We evaluated the rapid detection of rifampicin resistance in previously treated TB patients, directly from acidfast bacilli (AFB)-positive sputum using a phage-based test, FASTPlaque-Response (Biotec Laboratories Ltd, Ipswich, UK). The ability of rifampicin resistance to predict MDR-TB was also determined. A prospective study was done comparing performance of the rapid phage test with conventional culture and drug susceptibility testing (DST) in AFB-positive TB patients. Five primary health clinics and one TB referral centre in the Port Elizabeth Metropolitan area, Eastern Cape. Sensitivity, specificity and overall accuracy of the phage test were determined compared with gold standard culture and DST. Discrepant results were resolved by molecular detection of mutations conferring rifampicin resistance. The proportion of rifampicin-resistant strains that were MDR was also determined. Previously treated patients were at a high risk of MDRTB (35.7%). Sensitivity, specificity and overall accuracy of FASTPlaque-Response for rifampicin resistance determination were 95.4% (95% confidence interval (CI): 91.0 - 99.8%), 97.2% (95% CI: 94.5 - 99.9%) and 96.5% (95% CI: 94.1 - 98.9%) respectively compared with conventional DST (unresolved), calculated for specimens that had both FASTPlaque-Response and conventional DST results available. FASTPlaque-Response results were available in 2 days instead of 28 - 85 days with conventional DST. However, only 70.6% of FASTPlaque-Response results were interpretable compared with 86.3% of conventional DST results. The majority (95.5%) of rifampicinresistant strains were MDR-TB. Rapid detection of rifampicin resistance using FASTPlaque-Response could contribute to improved management of patients at risk of MDR-TB, such as previously treated patients. However, improvement in control of specimen-related contamination is needed to ensure that a higher proportion of FASTPlaque-Response results are interpretable. Where indicated, early modification of therapy could improve patient prognosis and reduce disease transmission.
- 1 September 2004
- Vol. 8 (9) , 1114-9
Simple, phage-based (FASTPplaque) technology to determine rifampicin resistance of Mycobacterium tuberculosis directly from sputum.
Cape Town, South Africa. To evaluate the performance of a simple, manual, phage-based test for determining rifampicin (RMP) resistance of Mycobacterium tuberculosis directly from smear-positive sputum specimens. A comparative study of the performance of the FASTPlaque (phage amplification) technology to determine RMP resistance directly from smear-positive sputum compared with isolation and the conventional indirect Middlebrook 7H11 agar proportion method. The FASTPlaque direct RMP test achieved sensitivity, specificity and overall accuracy of 100% (11/11), 100% (134/134) and 100% (145/145), respectively, compared with the conventional indirect susceptibility test method (resolved data). The FASTPlaque direct RMP test reported results within 2 days from receipt of the specimen, while the conventional method took between 27 and 103 days (mean +/- SD 33.2 +/- 7.2 days). FASTPlaque technology applied directly to smear-positive sputum offers performance comparable to conventional methods, with results available in 2 days instead of weeks to months. The test may form a useful part of DOTS-Plus programmes to combat multidrug-resistant tuberculosis, improving patient prognosis and reducing ongoing transmission of disease. It does not require specialised equipment, making it appropriate for high-burden countries.
- 1 September 2004
- Vol. 8 (9) , 1114-9
Simple, phage-based (FASTPplaque) technology to determine rifampicin resistance of Mycobacterium tuberculosis directly from sputum.
Cape Town, South Africa. To evaluate the performance of a simple, manual, phage-based test for determining rifampicin (RMP) resistance of Mycobacterium tuberculosis directly from smear-positive sputum specimens. A comparative study of the performance of the FASTPlaque (phage amplification) technology to determine RMP resistance directly from smear-positive sputum compared with isolation and the conventional indirect Middlebrook 7H11 agar proportion method. The FASTPlaque direct RMP test achieved sensitivity, specificity and overall accuracy of 100% (11/11), 100% (134/134) and 100% (145/145), respectively, compared with the conventional indirect susceptibility test method (resolved data). The FASTPlaque direct RMP test reported results within 2 days from receipt of the specimen, while the conventional method took between 27 and 103 days (mean +/- SD 33.2 +/- 7.2 days). FASTPlaque technology applied directly to smear-positive sputum offers performance comparable to conventional methods, with results available in 2 days instead of weeks to months. The test may form a useful part of DOTS-Plus programmes to combat multidrug-resistant tuberculosis, improving patient prognosis and reducing ongoing transmission of disease. It does not require specialised equipment, making it appropriate for high-burden countries.
- 1 February 2004
- Vol. 8 (2) , 240-7
Economic analysis of the diagnosis of smear-negative pulmonary tuberculosis in South Africa: incorporation of a new rapid test, FASTPlaqueTB, into the diagnostic algorithm.
To compare the cost-effectiveness of three diagnostic algorithms incorporating a new rapid test, FASTPlaqueTB, with the current National TB Control Programme (NTCP) algorithm for diagnosis of pulmonary tuberculosis in new smear-negative suspects in South Africa. A model of the outcome of patients screened using each diagnostic algorithm was established using published costs and performance data for each component of the algorithm. Direct health care provider costs associated with provision of each diagnostic strategy were determined. Overall performance, total cost, speed and accuracy of diagnosis were estimated for screening 1000 new TB suspects using each algorithm. The use of FASTPlaqueTB and culture algorithms enabled 28% more smear-negative TB patients to be diagnosed overall and was cheaper to implement than the NTCP algorithm (18,312-18,581 US dollars compared with 20,079 dollars). Fewer clinic visits were required to establish a diagnosis, reducing clinic workload and patient costs. FASTPlaqueTB enabled rapid and specific diagnosis of at least 50% of smear-negative TB patients within 2 days. The use of FASTPlaqueTB can assist in improving existing case detection strategies and may be cost-effectively integrated into the current diagnostic infrastructure, offering patients more rapid and reliable diagnosis whilst reducing the overall cost.
- 1 February 2004
- Vol. 8 (2) , 240-7
Economic analysis of the diagnosis of smear-negative pulmonary tuberculosis in South Africa: incorporation of a new rapid test, FASTPlaqueTB, into the diagnostic algorithm.
To compare the cost-effectiveness of three diagnostic algorithms incorporating a new rapid test, FASTPlaqueTB, with the current National TB Control Programme (NTCP) algorithm for diagnosis of pulmonary tuberculosis in new smear-negative suspects in South Africa. A model of the outcome of patients screened using each diagnostic algorithm was established using published costs and performance data for each component of the algorithm. Direct health care provider costs associated with provision of each diagnostic strategy were determined. Overall performance, total cost, speed and accuracy of diagnosis were estimated for screening 1000 new TB suspects using each algorithm. The use of FASTPlaqueTB and culture algorithms enabled 28% more smear-negative TB patients to be diagnosed overall and was cheaper to implement than the NTCP algorithm (18,312-18,581 US dollars compared with 20,079 dollars). Fewer clinic visits were required to establish a diagnosis, reducing clinic workload and patient costs. FASTPlaqueTB enabled rapid and specific diagnosis of at least 50% of smear-negative TB patients within 2 days. The use of FASTPlaqueTB can assist in improving existing case detection strategies and may be cost-effectively integrated into the current diagnostic infrastructure, offering patients more rapid and reliable diagnosis whilst reducing the overall cost.
- Open Access
- 28 February 2003
- Published by Academic Journals in AFRICAN JOURNAL OF BIOTECHNOLOGY
- Vol. 2 (2) , 40-45
The use of a novel phage-based technology as a practical tool for the diagnosis of tuberculosis in Africa
Sub-Saharan Africa has experienced a significant increase in tuberculosis cases in recent years, fuelled by high rates of TB-HIV co-infection in the region. The diagnosis of tuberculosis is based largely on clinical assessment, sputum smear microscopy and chest radiography. Although smear microscopy is useful for detecting the most infectious cases, a significant portion of cases are negative on sputum smears, making diagnosis more difficult. New tests are urgently needed. The FASTPlaqueTB test, a bacteriophage-based method, has been evaluated in several studies in Africa and elsewhere. Studies in South Africa and Pakistan reported that between half and two-thirds of smear-negative culture-positive TB cases were detected by theFASTPlaqueTB test within 2 days. This suggests a beneficial role for this test in the early diagnosis of clinically suspected smear-negative cases. The same technology has been applied to develop a rapid test to indicate multi-drug resistant TB,FASTPlaqueTB-MDRi. This test gave equivalent results to conventional drug susceptibility methods, but with more rapid results. The tests are simple to perform and require no specialised equipment, making the technology suitable for widespread implementation. Key words: Tuberculosis, bacteriophage, diagnostic test, phage amplification technology, multi-drug resistance, drug susceptibility test.
- 28 February 2003
- Published by Academic Journals in AFRICAN JOURNAL OF BIOTECHNOLOGY
- Vol. 2 (2) , 40-45
Open AccessThe use of a novel phage-based technology as a practical tool for the diagnosis of tuberculosis in Africa
Sub-Saharan Africa has experienced a significant increase in tuberculosis cases in recent years, fuelled by high rates of TB-HIV co-infection in the region. The diagnosis of tuberculosis is based largely on clinical assessment, sputum smear microscopy and chest radiography. Although smear microscopy is useful for detecting the most infectious cases, a significant portion of cases are negative on sputum smears, making diagnosis more difficult. New tests are urgently needed. The FASTPlaqueTB test, a bacteriophage-based method, has been evaluated in several studies in Africa and elsewhere. Studies in South Africa and Pakistan reported that between half and two-thirds of smear-negative culture-positive TB cases were detected by theFASTPlaqueTB test within 2 days. This suggests a beneficial role for this test in the early diagnosis of clinically suspected smear-negative cases. The same technology has been applied to develop a rapid test to indicate multi-drug resistant TB,FASTPlaqueTB-MDRi. This test gave equivalent results to conventional drug susceptibility methods, but with more rapid results. The tests are simple to perform and require no specialised equipment, making the technology suitable for widespread implementation. Key words: Tuberculosis, bacteriophage, diagnostic test, phage amplification technology, multi-drug resistance, drug susceptibility test.